Background Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization
or death in older patients and those with underlying conditions. Sotrovimab is a pan-…

Importance Older patients and those with comorbidities who are infected with SARS-CoV-2
may be at increased risk of hospitalization and death. Sotrovimab is a neutralizing antibody …

Background The novel prodrug tenofovir alafenamide delivers the nucleotide reverse
transcriptase inhibitor tenofovir to target cells more efficiently at a lower dose than tenofovir …

Background & Aims Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to
treat patients with chronic hepatitis B virus (HBV) infection at a lower dose than tenofovir …

VIR-7831 and VIR-7832 are dual action monoclonal antibodies (mAbs) targeting the spike
glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). VIR-7831 …

Background & Aims Tenofovir disoproxil fumarate (TDF) is a first‐line treatment for chronic
hepatitis B (CHB). We aimed to describe the efficacy and safety profiles of TDF treatment for …

Influenza virus infections are a global public health problem, with a significant impact of
morbidity and mortality from both annual epidemics and pandemics. The current strategy for …

To successfully complete their replication cycles, picornaviruses modify several host
proteins to alter the cellular environment to favor virus production. One such target of viral …

Background & Aims Current therapy for chronic hepatitis B virus (cHBV) infection involves
lifelong treatment. New treatments that enable HBV functional cure would represent a clinically …

Tenofovir alafenamide (TAF) has shown equivalent efficacy and improved safety profiles for
patients with chronic hepatitis B (CHB) compared to tenofovir disoproxil fumarate (TDF). …